CA98420N1050
CA98420N1050
Xenon Pharmaceuticals Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 7.500.000 | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 380.570.000 | 279.298.000 | 36.3% | |
| Operating Income | -373.070.000 | -279.298.000 | 33.6% |
| Pretax Income | -344.894.000 | -238.419.000 | 44.7% |
| Net Income Common Stockholders | -345.910.000 | -234.330.000 | 47.6% |
| -- | -- | -- | |
| -- | -- | -- |